Biocytogen Announces Collaboration with FineImmune to Develop TCR-Mimic Antibody-Based Cell Therapy
15.9.2022 15:02:00 EEST | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD. (“FineImmune”) to co-develop cell-based therapeutic drugs targeting intracellular tumor-associated antigens. Biocytogen will use its proprietary TCR-mimic antibody platform to discover fully human antibody sequences that will be further developed using FineImmune’s unique cell therapy platform.
Biocytogen’s TCR-mimic antibody development platform utilizes its proprietary fully human antibody RenMiceTM (RenMabTM and RenLite® mice) that have been further engineered to express a human leukocyte antigen (HLA) gene. Antibodies against intracellular tumor-associated antigens are subjected to advanced high-throughput antibody screening technologies to discover antibodies with high specificity and affinity.
“Most tumor antigens are intracellular, and our TCR-mimic platform provides a solution for developing antibodies against these valuable targets,” said Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen. “TCR-mimic antibodies generated by our TCR-mimic platform have potentials to be developed into multiple drug modalities such as T cell engagers, bispecific/multispecific antibodies and CAR-T therapies. We are pleased to collaborate with FineImmune to explore the application of our antibodies in the field of cell therapies.”
FineImmune is a pioneering T cell therapy company, and has solved multiple critical barriers in the microenvironment of solid tumors by using multiple proprietary technology platforms, such as GSOP for T-cell engineering, HAP for TCR identification, CMP for personalized TCR-T cell production and in vivo T-cell delivery platform (TDP). FineImmune’s product pipelines include TCR-T, CAR-T, TAL, TIL, etc. The company developed the first personalized neoantigen-specific TCR-T cell therapy, which is in phase I clinical trial now. In addition, FineImmune possesses technologies for the precision prediction of the efficacy and side effects of immunotherapy, enabling healthcare professionals to provide effective and safe immunotherapy to patients with common malignant tumors.
“T cells play an important role in treating cancers. Biocytogen’s advanced TCR-mimic platform makes it possible for us to develop T cell therapies against crucial but low-expressed intracellular tumor antigens,” said Dr. Penghui Zhou, Founder and Chief Technology Officer of FineImmune. “We focus on providing efficient and safe immunotherapy using advanced technologies. This collaboration will promote the development of new cell therapeutic drugs and the expansion of the potential of immunotherapy to benefit patients.”
About the TCR-Mimic Platform
Biocytogen’s T Cell Receptor (TCR)-Mimic platform utilizes HLA-expressing fully human antibody mice (HLA/RenMice) to generate antibodies to intracellular tumor-associated antigens when immunized with MHC-antigen-peptide complexes. Subsequently, Biocytogen’s high-throughput antibody screening platform aims to swiftly identify TCR-mimic antibodies with higher specificity and affinity than endogenous TCRs derived from patients. Currently, antibody sequences against multiple intracellular targets have been obtained, and their efficacies have been verified in vitro and in vivo. Fully human antibody sequences obtained from the TCR-mimic platform can empower the development of T cell engagers, bispecific/multispecific antibodies, and CAR-T therapies.
About Biocytogen
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM /RenLite® mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop antibody drugs for more than 1000 targets, known as Project Integrum, and has entered ongoing collaborations with dozens of partners worldwide to produce a variety of first-in-class and/or best-in-class antibody drugs. The company's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. On September 1, 2022, Biocytogen was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 02315.HK. For more information, please visit http://en.biocytogen.com.cn.
About FineImmune
Guangzhou FineImmune Biotechnology Co., Ltd. is an innovation driven company based in China. The company is mainly engaged in the development of solid tumor immunotherapy drugs and related businesses. It has solved key technical bottlenecks in solid tumor immunotherapy and possesses core technologies. A number of T-cell therapy products for solid tumors are in clinical trials, as well as diagnostic reagents for accurate identification of effective populations. It has a 2000 square meter immunotherapy R&D laboratory and a GMP production workshop for cell therapy products in Guangzhou Science City. The company's individualized TCR-T cell therapy product (new drug) has been carried out clinical research in the Affiliated Tumor Hospital of Sun Yat sen University. At present, more than 20 immune cell therapy products and technologies are under research and development. For more information, please visit http://www.fineimmu.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005284/en/
Contact information
Biocytogen
Platform and Assets:
BD-Licensing@biocytogen.com
Media:
pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BanyanGlobal Family Business Advisors Named Family Business Advisory Practice of the Year at the STEP Private Client Awards for the Fourth Time14.10.2026 16:05:00 EEST | Press release
BanyanGlobal Family Business Advisors ("Banyan") has been named Family Business Advisory Practice of the Year at the 21st annual STEP Private Client Awards, one of the most respected international honors in the private client profession. It is the fourth time Banyan has won the category, following wins in 2018, 2020 and 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261013883351/en/ Kelly Greig, STEP Board Member and Dennis Jaffe, BanyanGlobal Family Business Advisors at the awards ceremony. BanyanGlobal won the Family Business Advisory Practice of the Year at the 21st Annual STEP Private Client Awards. The independent judging panel singled out Banyan's approach: "BanyanGlobal Family Business Advisors has redefined family business advisory by combining governance with helping families build skills and confidence for long-term ownership. Its innovative approach and long-standing client relationships helped make it the s
Telekom Srbija Group Expands AI Investment and Strengthens U.S. Technology Partnerships14.10.2026 16:02:00 EEST | Press release
Following the October 1 agreement between Serbia and the United States to strengthen cooperation in artificial intelligence (AI), Telekom Srbija Group is expanding its AI investment and deepening relationships with leading U.S. technology companies as part of its strategy to develop the next generation digital services. As part of these efforts, Telekom Srbija Group has engaged with the U.S. State Department, Department of Commerce and Export-Import Bank to explore opportunities for technology cooperation and project financing, with the ambition of becoming a preferred regional partner for U.S. companies. “Artificial intelligence represents one of the greatest opportunities for the future of telecommunications and digital services,” said Vladimir Lučić, CEO of Telekom Srbija Group. “We have been investing in this technology for several years, and our focus is now on accelerating its practical application. By combining AI innovation with our expanding 5G infrastructure and international
Wolters Kluwer names Alberto de Benito Aznar General Manager of Audit & Assurance14.10.2026 16:00:00 EEST | Press release
Wolters Kluwer, a global leader in professional information, software solutions and services, today announced the appointment of Alberto de Benito Aznar as General Manager of its Audit & Assurance business, part of the Corporate Performance & ESG division. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014786222/en/ De Benito Aznar returns to a business and market he knows well. He began his Wolters Kluwer career more than 10 years ago in Corporate Strategy and subsequently led operations for Audit & Assurance before serving most recently as General Manager of Corporate Tax. “Alberto brings a strong combination of strategic, operational and commercial leadership to Audit & Assurance,” said Maria Montenegro, CEO of Corporate Performance & ESG at Wolters Kluwer. “His leadership of Corporate Tax, combined with his previous experience in Audit & Assurance, gives him a valuable perspective as we build on TeamMate’s strong posi
Lenovo Uncovers What Happens When Entrepreneurs Look Beyond Borders for Support14.10.2026 16:00:00 EEST | Press release
Today, Lenovo debuts the first episode of its new documentary series from Backing Every Business, its global initiative designed to connect small businesses with the people, technology and support they need to grow and thrive. The series features five businesses participating in Twinning, Lenovo’sprogram that brings small business founders from around the world together, connecting them through mentorship across shared growth goals, access to resources including technology, AI training, funding designed to help address real business challenges and turn new ideas into action. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014736241/en/ The four-part series follows entrepreneurs from Japan, Mexico, the U.K. and the U.S. as they step inside one another’s businesses, experience unfamiliar industries and cultures and share the knowledge they have gained from building their own businesses. A meeting between strangers evolves in
Airship Achieves ISO 42001 Certification, Clearing the Path for Responsible Enterprise AI14.10.2026 16:00:00 EEST | Press release
Airship, the mobile-first customer experience company, today announced it has achieved ISO 42001 certification, the global benchmark for Artificial Intelligence Management Systems (AIMS). Certified following an independent audit by A-LIGN, Airship is among the first in the CX industry to earn this standard across its platform. This certification provides enterprise brands with an independently verified foundation to scale AI-driven customer journeys—eliminating procurement hurdles while supporting compliance, data privacy, and EU AI Act readiness. Solving the Enterprise AI Paradox Enterprise product and marketing leaders face mounting pressure to innovate with AI, yet fears of data leaks, hallucinations, and regulatory non-compliance continue to stall adoption. Airship’s ISO 42001 certification addresses those concerns: an independent auditor confirmed that Airship governs its AI capabilities through a documented, tested, and continually improving management system. According to Forres
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom